US equities |
SPCX $166.81 ▲+4.94% NVDA $236.85 ▲+1.24% MU $1,064.62 ▼-0.96% TSLA $377.04 ▲+1.74% MSFT $524.94 ▲+1.43% SNDK $1,707.37 ▼-0.73% INTC $117.50 ▼-1.53% META $742.83 ▲+2.03%
FinancialContent

Articles published by TCR2 Therapeutics

News headline image
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
TCR² Therapeutics Announces Pipeline Priorities for 2023
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
News headline image
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR